Overview

Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
0
Participant gender:
All
Summary
This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Korea Otsuka Pharmaceutical Co., Ltd.
Treatments:
Aripiprazole
Criteria
Inclusion Criteria:

- Patient with a schizophrenia or schizoaffective disorder or bipolar disorder according
to DSM-IV criteria

- Age: more than 18 years of age

Exclusion Criteria:

- Unqualified patients judged by study investigator(s)